Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis

References

• Jiao T, Platt RW, Douros A, et al. Prescription patterns for the use of antihypertensive drugs for primary prevention among patients with hypertension in the United Kingdom. Am J Hypertens. 2022;35(1):42–53.
   PubMed Web of Science ®Google Scholar
• Reubi FC, Cottier PT. Effects of reduced glomerular filtration rate on responsiveness to. Circulation. 1961;23(February 1961):200–210.
   PubMedGoogle Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:1269–1324.
   PubMed Web of Science ®Google Scholar
• Floege J, Cervelli MJ, Graeme R. Principles of drug therapy, dosing, and prescribing in chronic kidney disease and renal replacement therapy. St Louis (MO): Elsevier Saunders; 2010.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for themanagement of arterial hypertension. 2018;39:3021–3104.
   Google Scholar
• Dussol B, Moussi-Frances J, Morange S, et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14(1):32–37.
   PubMed Web of Science ®Google Scholar
• Cirillo M, Marcarelli F, Mele AA, et al. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension. 2014;63(4):692–697.
   PubMed Web of Science ®Google Scholar
• Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26(3):394–400.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA J Am Med Assoc. 2002;288(23):2981–2997. http://www.ncbi.nlm.nih.gov/pubmed/12479763%5Cnhttp://jama.jamanetwork.com/article.aspx?articleid=195626
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10.
   PubMedGoogle Scholar
• Research Rabbit. https://researchrabbitapp.com/.
   Google Scholar
• Fliser D, Schröter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46(2):482–488.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4(NOV):1–12.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–2519.
   PubMed Web of Science ®Google Scholar
• Dussol B, Moussi-Frances J, Morange S, et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant. 2005;20(2):349–353.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Pappas MK, et al. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–182.
   PubMed Web of Science ®Google Scholar
• Layton AT, Edwards A, Vallon V. Adaptive changes in GFR, tubular morphology, and transport in subtotal nephrectomized kidneys: modeling and analysis. Am J Physiol Renal Physiol. 2017;313(2):F199–F209.
   PubMed Web of Science ®Google Scholar
• Pourafshar N, Alshahrani S, Karimi A, et al. Thiazide therapy in chronic kidney disease: renal and extra renal targets. Curr Drug Metab. 2018;19(12):1012–1020.
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Stocker SL, Wittwer MB, et al. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 2013;53:503–529.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Nagle MA, Kouznetsova VL, et al. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res. 2011;10(6):2842–2851.
   PubMed Web of Science ®Google Scholar
• Uwai Y, Saito H, Hashimoto Y, et al. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000;295(1):261–265. http://jpet.aspetjournals.org/content/295/1/261.abstract
   PubMed Web of Science ®Google Scholar
• Sirich TL, Aronov PA, Plummer NS, et al. Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int. 2013;84(3):585–590.
   PubMed Web of Science ®Google Scholar
• Tampe D, Schridde L, Korsten P, et al. Different patterns of kidney fibrosis are indicative of injury to distinct renal compartments. Cells. 2021;10(8):2014–2015.
   PubMed Web of Science ®Google Scholar
• Lowenstein J, Grantham JJ. Residual renal function: a paradigm shift. Kidney Int. 2017;91(3):561–565.
   PubMed Web of Science ®Google Scholar
• Chapron A, Shen DD, Kestenbaum BR, et al. Does secretory clearance follow glomerular filtration rate in chronic kidney diseases? Reconsidering the intact nephron hypothesis. Clin Transl Sci. 2017;10(5):395–403.
   PubMed Web of Science ®Google Scholar
• Ronco P, Rovin B, Schlöndorff D, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–S87. https://www.elsevier.com/books-and-journals/
   PubMedGoogle Scholar
• Fujihara CK, Malheiros DMAC, Zatz R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol - Ren Physiol. 2007;292(6):1810–1818.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299–308.
   PubMed Web of Science ®Google Scholar
• Nigam SK, Wu W, Bush KT, et al. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10(11):2039–2049.
   PubMed Web of Science ®Google Scholar